StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

Vanda Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Vanda Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$139.14M. For fiscal 2025 it was -$109.44M. The highest annual figure on record is $169.34M in fiscal 2009.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$109.44M–
FY2024Dec 31, 2024-$15.76M-223.1%
FY2023Dec 31, 2023$12.80M-60.0%
FY2022Dec 31, 2022$31.98M-50.2%
FY2021Dec 31, 2021$64.21M+24.0%
FY2020Dec 31, 2020$51.78M+12.7%
FY2019Dec 31, 2019$45.95M+53.2%
FY2018Dec 31, 2018$29.99M–
FY2017Dec 31, 2017-$1.98M–
FY2016Dec 31, 2016-$8.10M-165.1%
FY2015Dec 31, 2015$12.45M–
FY2014Dec 31, 2014-$81.55M–
FY2013Dec 31, 2013-$39.59M–
FY2012Dec 31, 2012-$44.92M–
FY2011Dec 31, 2011-$28.41M–
FY2010Dec 31, 2010-$10.90M-106.4%
FY2009Dec 31, 2009$169.34M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$28.44M–
Q2 FY2026Jun 30, 2026-$31.07M–
Q1 FY2026Mar 31, 2026-$50.22M–
Q4 FY2025Dec 31, 2025-$29.42M–
Q3 FY2025Sep 30, 2025-$31.63M–
Q2 FY2025Jun 30, 2025-$15.25M–
Q1 FY2025Mar 31, 2025-$33.15M-537.9%
Q4 FY2024Dec 31, 2024-$1.82M–
Q3 FY2024Sep 30, 2024-$14.58M–
Q2 FY2024Jun 30, 2024-$6.93M–
Q1 FY2024Mar 31, 2024$7.57M-76.2%
Q4 FY2023Dec 31, 2023-$3.73M-139.6%
Q3 FY2023Sep 30, 2023-$2.05M-116.0%
Q2 FY2023Jun 30, 2023-$13.22M-332.5%
Q1 FY2023Mar 31, 2023$31.80M+686.0%
Q4 FY2022Dec 31, 2022$9.42M-64.6%
Q3 FY2022Sep 30, 2022$12.84M+36.6%
Q2 FY2022Jun 30, 2022$5.69M-70.1%
Q1 FY2022Mar 31, 2022$4.05M-56.0%
Q4 FY2021Dec 31, 2021$26.61M+37.8%
Q3 FY2021Sep 30, 2021$9.40M+0.2%
Q2 FY2021Jun 30, 2021$19.02M-20.8%
Q1 FY2021Mar 31, 2021$9.19M–
Q4 FY2020Dec 31, 2020$19.30M+97.1%
Q3 FY2020Sep 30, 2020$9.37M+56.3%
Q2 FY2020Jun 30, 2020$24.01M+17.0%
Q1 FY2020Mar 31, 2020-$907.00K-109.4%
Q4 FY2019Dec 31, 2019$9.79M-35.9%
Q3 FY2019Sep 30, 2019$6.00M-31.0%
Q2 FY2019Jun 30, 2019$20.52M+367.2%
Q1 FY2019Mar 31, 2019$9.64M+488.7%
Q4 FY2018Dec 31, 2018$15.26M+340.4%
Q3 FY2018Sep 30, 2018$8.69M+301.0%
Q2 FY2018Jun 30, 2018$4.39M–
Q1 FY2018Mar 31, 2018$1.64M–
Q4 FY2017Dec 31, 2017$3.47M–
Q3 FY2017Sep 30, 2017$2.17M–
Q2 FY2017Jun 30, 2017-$2.26M–
Q1 FY2017Mar 31, 2017-$5.36M–
Q4 FY2016Dec 31, 2016-$1.18M–

More Vanda Pharmaceuticals figures

See a number that looks wrong?